ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions
View by Date

Tuesday, October 23, 2018

2:30PM-4:00PM
Abstract Number: 2792
The Effect of B Cell Targeted Therapies on Autoantibodies and Excessive Neutrophil Extracellular Trap Formation in Systemic Lupus Erythematosus
5T085 ACR Abstract: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (2791–2796)
2:30PM-4:00PM
Abstract Number: 2834
The Presence of Anti-Rituximab Antibodies Predicts Infusion-Related Reactions in Patients with Systemic Lupus Erythematosus
5T090 ACR Abstract: SLE–Clinical III: Translational Aspects (2832–2837)
2:30PM-4:00PM
Abstract Number: 2829
The Response to TNF-Blockers Treatment of Spa Patients Is Influenced By the Interplay between HLA-B27 and Gut Microbiota Composition at Baseline
5T091 ACR Abstract: Spondyloarthritis Incl PsA–Clinical IV: Comorbid/Related Conditions(2826–2831)
2:30PM-4:00PM
Abstract Number: 2828
Utility of Fecal Calprotectin Levels for the Diagnosis of Inflammatory Bowel Disease in Patients with Spondylorarthritis
5T091 ACR Abstract: Spondyloarthritis Incl PsA–Clinical IV: Comorbid/Related Conditions(2826–2831)
4:00PM-6:00PM
Abstract Number: L18
A Randomized Controlled 24-Week Trial Evaluating the Safety and Efficacy of Blinded Tapering Versus Continuation of Long-Term Prednisone (5 mg/day) in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab
5T113 Abstracts: Late-Breaking Abstract Session
4:00PM-6:00PM
Abstract Number: L17
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psa: Results from a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
5T113 Abstracts: Late-Breaking Abstract Session
4:00PM-6:00PM
Abstract Number: L20
Efficacy and Safety of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Hip or Knee
5T113 Abstracts: Late-Breaking Abstract Session
4:00PM-6:00PM
Abstract Number: L16
Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
5T113 Abstracts: Late-Breaking Abstract Session
4:00PM-6:00PM
Abstract Number: L15
The Diagnostic Accuracy of PET/CT Scan of the Head, Neck and Thorax Compared with Temporal Artery Biopsy in Patients Newly Suspected of Having GCA
5T113 Abstracts: Late-Breaking Abstract Session
4:00PM-6:00PM
Abstract Number: L19
Transcutaneous Electrical Nerve Stimulation (TENS) Reduces Pain and Fatigue and Improves Disease Impact in Women with Fibromyalgia: A Randomized Controlled Trial
5T113 Abstracts: Late-Breaking Abstract Session
4:30PM-6:00PM
Abstract Number: 2853
A Protective Langerhans Cell-Keratinocyte Axis That Is Dysfunctional in Photosensitivity
5T105 ACR Abstract: Innate Immunity (2850–2855)
4:30PM-6:00PM
Abstract Number: 2857
An Electronic Audit, Reporting, and Data Correction System Improves the Quantity and Quality of Observational Data Collected for US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
5T106 ACR Abstract: Measures of Healthcare Quality I: QI in RA (2856–2861)
4:30PM-6:00PM
Abstract Number: 2866
Biologic Refractory Disease in a Cohort Study of Children and Young People with Juvenile Idiopathic Arthritis from the United Kingdom
5T107 ACR Abstract: Pediatric Rheum–Clinical II: Treatment Update (2862–2867)
4:30PM-6:00PM
Abstract Number: 2865
Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission
5T107 ACR Abstract: Pediatric Rheum–Clinical II: Treatment Update (2862–2867)
4:30PM-6:00PM
Abstract Number: 2887
Chronic Pain and Assessment of Pain Sensitivity in Patients with Established Axial Spondyloarthritis – a Cross-Sectional Study
5T112 ACR Abstract: Spondyloarthritis Incl PsA–Clinical V: Tx of PsA & Peripheral SpA (2886–2891)
  • «Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology